{"title":"Cancer Stem Cells as a Therapeutic Target: Current Clinical Development and Future Prospective.","authors":"Alex Philchenkov, Anna Dubrovska","doi":"10.1093/stmcls/sxad092","DOIUrl":null,"url":null,"abstract":"<p><p>The key role of cancer stem cells (CSCs) in tumor development and therapy resistance makes them essential biomarkers and therapeutic targets. Numerous agents targeting CSCs, either as monotherapy or as part of combination therapy, are currently being tested in clinical trials to treat solid tumors and hematologic malignancies. Data from ongoing and future clinical trials testing novel approaches to target tumor stemness-related biomarkers and pathways may pave the way for further clinical development of CSC-targeted treatments and CSC-guided selection of therapeutic regimens. In this concise review, we discuss recent progress in developing CSC-directed treatment approaches, focusing on clinical trials testing CSC-directed therapies. We also consider the further development of CSC-assay-guided patient stratification and treatment personalization.</p>","PeriodicalId":231,"journal":{"name":"STEM CELLS","volume":" ","pages":"173-199"},"PeriodicalIF":4.0000,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"STEM CELLS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/stmcls/sxad092","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The key role of cancer stem cells (CSCs) in tumor development and therapy resistance makes them essential biomarkers and therapeutic targets. Numerous agents targeting CSCs, either as monotherapy or as part of combination therapy, are currently being tested in clinical trials to treat solid tumors and hematologic malignancies. Data from ongoing and future clinical trials testing novel approaches to target tumor stemness-related biomarkers and pathways may pave the way for further clinical development of CSC-targeted treatments and CSC-guided selection of therapeutic regimens. In this concise review, we discuss recent progress in developing CSC-directed treatment approaches, focusing on clinical trials testing CSC-directed therapies. We also consider the further development of CSC-assay-guided patient stratification and treatment personalization.
期刊介绍：
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology.
STEM CELLS covers:
Cancer Stem Cells,
Embryonic Stem Cells/Induced Pluripotent Stem (iPS) Cells,
Regenerative Medicine,
Stem Cell Technology: Epigenetics, Genomics, Proteomics, and Metabonomics,
Tissue-Specific Stem Cells,
Translational and Clinical Research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
